Updates are available Correction dated 2025-10-29

Article History

Received: 7 March 2025

Accepted: 19 July 2025

First Online: 19 August 2025

Change Date: 29 October 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40620-025-02457-5

Declarations

:

: The study adhered to the principles of the Declaration of Helsinki and received ethical approval from the Ethical Review Board of Fukushima Medical University (Approval number: ippan2021-292).

: The present study complies with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects. This study does not contain any studies with animals.

: All participants provided written informed consent and completed paper-based questionnaires.

: Not applicable.

: Ryohei Inanaga has received payment for speaking and educational events from Vantive Japan. Tatsunori Toida has received consulting fees from Astellas Pharma Inc., payment, and speaking. Educational events from Torii Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., AstraZeneca K.K., Nobelpharma Co., Ltd., and Novo Nordisk Pharma Ltd. Takumi Toishi received payment for speaking and educational events from Otsuka Pharmaceuticals. Masatoshi Matsunami received payments for speaking and educational events from Astellas Pharma Inc. and Baxter Co., Ltd. Tomo Suzuki has received payment for speaking and educational events from Astellas Pharma Inc, AstraZeneca K.K, Vantive Japan, Daiichi Sankyo Co., Ltd., Janssen Pharmaceutical K.K, Kaneka Medix Corp, Kissei Pharmaceutical Co., Ltd., Kowa Co., Ltd., Kyowa Kirin Co., Ltd, Mochida Pharmaceutical Co., Ltd., Nobelpharma Co., Ltd, Novartis Pharma K.K., Novo Nordisk Pharma., Ltd., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical, Terumo Corp, and Torii Pharmaceutical Co., Ltd. Noriaki Kurita has received consulting fees from GlaxoSmithKline K.K. and payment for speaking and educational events from Eisai Co., Ltd., Taisho Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., GlaxoSmithKline K.K., Takeda Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., and Baxter Corporation.

: All data produced in the present work are contained in the manuscript.

: This study was supported by JSPS KAKENHI (Grant numbers: JP19KT0021, JP22K19690, and JP23K16271). The funder had no role in study design, data collection and analysis, publication decisions, or manuscript preparation.

: Research idea and study design: Yusuke Kanakubo, Ryohei Inanaga, Tatsunori Toida, Noriaki Kurita; data acquisition: Yusuke Kanakubo, Ryohei Inanaga, Mamiko Ukai, Takumi Toishi, Atsuro Kawaji, Masatoshi Matsunami, Tadao Okada, Yu Munakata, Tomo Suzuki; data analysis/interpretation: Yusuke Kanakubo, Ryohei Inanaga, Tatsunori Toida, Tetsuro Aita, Tomo Suzuki, Noriaki Kurita; statistical analysis: Yusuke Kanakubo, Noriaki Kurita; supervision or mentorship: Noriaki Kurita. Each author contributed important intellectual content during manuscript drafting or revision, agreed to be personally accountable for the individual's contributions, and ensured that questions about the accuracy or integrity of any portion of the work, even one in which the author was not directly involved, were appropriately investigated and resolved, including documentation in the literature, if appropriate.